论文部分内容阅读
在人胎脾细胞ＬＡＫ活性诱导，增殖反应能力的基础上，探讨了人胎脾ＬＡＫ细胞制备，质量控制及临床应用的安全性，可靠性及疗效。共治疗５２例晚期恶性肿瘤病人。结果显示：全部病人都有不同程度地改善了一般症状和体征，提高了生活质量，对减轻癌性疼痛和消除癌性胸腹水效果明显。５２例患者中，ＣＲ６例（１１％），ＰＲ１４例（２７％）。以人胎脾细胞作为ＬＡＫ前体细胞，取代了传统的自体或异体外周血淋巴细胞，ＬＡＫ细胞获取量大，治疗效果肯定，副作用轻，具有一定的应用价值。
Based on the ability of LAK activity induction and proliferation in fetal spleen cells, the safety, reliability and efficacy of human fetal spleen LAK cells preparation, quality control and clinical application were discussed. A total of 52 patients with advanced malignant tumors were treated. The results showed that all the patients had improved the general symptoms and signs to different degrees, improved the quality of life, and had a significant effect in reducing cancer pain and eliminating cancerous pleural effusion. Of the 52 patients, 6 were CR (11%) and 14 were PR (27%). Using human fetal spleen cells as LAK precursor cells to replace the traditional autologous or allogeneic peripheral blood lymphocytes, LAK cells have a large amount of acquisition, a positive therapeutic effect, and mild side effects, which have certain application value.